{"name":"Allorion Therapeutics Inc","slug":"allorion-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ARTS-011","genericName":"ARTS-011","slug":"arts-011","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ARTS-011","genericName":"ARTS-011","slug":"arts-011","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNQTlYaEZqN3JLelZ3dHFJaEZTbDZMdVFXQWxvdThGbl9PMk1EZmlGcUl0ZnlQTnF2ZDlYN2xsMmdmcDFPaEhsNFVPSWZhRVB3aDF6MVBXY1d5RmJwT0ozWi1DMkJMYU1UTXRoV2FBaWpib25tZ29tR3NXUXN4TVp0ZFJIUW42RTZiQUl1US16N3UyUlQwNmZsUGhsYnpvYjh4ZEdkLTZlckpiOVhjZmxYSnRtOHhVTWFRdVJmWWZMUWxYOGVJVlJxX2R2dUZJRUQ3SHhNMA?oc=5","date":"2025-12-01","type":"pipeline","source":"ascopost.com","summary":"Exploratory FLAURA2 Analysis Confirms Overall Survival Benefit for Osimertinib in NSCLC Subgroups - ascopost.com","headline":"Exploratory FLAURA2 Analysis Confirms Overall Survival Benefit for Osimertinib in NSCLC Subgroups","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBzZ2lyT3ZyVE9vNHBfLVhpRVlNN0JCX3l4YU1LUGxIZExWNm0tZldkLXRYU2dWYUpsWUpoZUFIR3Nsamh4YnRUNlgwcjVUdWpSNFNz?oc=5","date":"2025-09-22","type":"pipeline","source":"FirstWord Pharma","summary":"Avenzo, Ensoma each add over $50M to their coffers - FirstWord Pharma","headline":"Avenzo, Ensoma each add over $50M to their coffers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBmRnpJT2ZrTEg4UjNjaTVRRkxSNlFDQTZnU0ZoSm1zT3dybXZLYmtOdzZyajdzWUxUMGY3bG1nWjFtNGxRTDhnX3hwbHVkNmtTWG1v?oc=5","date":"2025-02-20","type":"deal","source":"FirstWord Pharma","summary":"AstraZeneca to acquire FibroGen's China unit for $160M - FirstWord Pharma","headline":"AstraZeneca to acquire FibroGen's China unit for $160M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOdmVKWFZLWjNSUkxpNXNMUmxXYkFqNk1acExGN01QSkFuUmp2RGEyMnZobkZnMG9hQXFDM2Q2TUFVQmsxc2ZjcE5hYmZ6bzZncGxyUFI4SHI3SXhRZl93T0x0VEpfaThvVy1Na2RoTjdiSWV4TTZQYjdveDhxamVGbnFnSFc0Z1I0MUk4RDdDaG43UFRZMmRXNzRZODVKVTZDbmJDdg?oc=5","date":"2025-01-29","type":"pipeline","source":"BioCentury","summary":"The NewCo boom signals China’s galloping speed of innovation - BioCentury","headline":"The NewCo boom signals China’s galloping speed of innovation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQaWczTXJrR2NuNW5uZ3VtMHVWSElQUkJRV0lkVExkNXZvN3B4TGxUMG0yRWRDTkN1WnMtUU5XNkVYRHI5LWhwTnRiaHhSUDFIb2tJRjJVWFRoSEwtRi1vaDhadGpsMlVBUTNZQTA0R0lqM1BzSmhuVmlNOGR2NHJXd1U2UmhjNXlfN3U1MDFrbWNHWlFrZjByeEF4eS1fZVB4QWhWMFhxR2dUMGt6MXFtMkJ1Sm4wZGczSTNYeEUyMzI5ZjlKN2c?oc=5","date":"2024-04-11","type":"pipeline","source":"Fierce Biotech","summary":"For Chinese biotechs, the out-licensing business is scorching hot. Could geopolitics rain on their parade? - Fierce Biotech","headline":"For Chinese biotechs, the out-licensing business is scorching hot. Could geopolitics rain on their parade?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOMTBycmFDa3VYTWMxaWRmNE5qZTV4YWQzcnh2NHRmVW5kRm44WjhnRk84WnR6QXNIOWk3SG40UTNKbmtyRU1lMTlxTlVILWxOdUQ4UlZDcUlpb01OVVZROXdPaGQ3TmlCUEhrRlFCVk9yaUJWYzlFa3FqaVhnNlVuMndUdUgyWHlxR09zaC1KdjlockNPUmRVczQ5dkNsQ3dTZDFKSg?oc=5","date":"2024-01-09","type":"deal","source":"BioWorld News","summary":"Argo, Novartis sign two deals for CV assets for potentially $4B+ - BioWorld News","headline":"Argo, Novartis sign two deals for CV assets for potentially $4B+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNZk9RUzhsSE5WcWlPOUZPOXZyeVA0em56bmRCZzI1ZC1SSXd6YnM0bW1UbmduTjNwcmNzZlZTVkhobW1MbmozMDJlckpBSk9yaGpkSmEyRVZXTURHakhQbzctdkZucy1LY1ZfN1FkN1RiVGp1RjJpUTdvMHQwbXB0THlNSzB0SE5sQUVNclpjNWZpUkljOGo0S1NHdjE4dFBiOWt5TnRSbFQ0Z0NiVVhLQkRuQQ?oc=5","date":"2024-01-05","type":"deal","source":"Fierce Pharma","summary":"Fierce Pharma Asia—Deal spree by AstraZeneca, J&J, Roche, Boehringer and more; Big Pharma’s China strategy - Fierce Pharma","headline":"Fierce Pharma Asia—Deal spree by AstraZeneca, J&J, Roche, Boehringer and more; Big Pharma’s China strategy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxPTUhnZkFEVnNuQ1hIc2JJZ1VGV0RUV3JmSHVpWlRBZHR3M3RmOEJRWEVSb2doMzhQV29TM0ZnamI3WGNockMyNUZLbWVJQlM5UEdxV0FzaWdxZXFzYnRzN2s4Ymlza284QWRhazdjUF82R3dVOVZGNU1sU1BuTG95QXBrVHl5V1M3NjU1YXBuUktOWi1fT1Jta3k1QjNXaHY2N0taU1BrSkI0TVhIVEhDdE5yLUJpdmxkbWx6OGI4Q0N1WnM1WTA4enpPR1A1Sy1DdmdDakU5VXhzdUx2NDVYMW9qQWtxejNKRGNwSHZn?oc=5","date":"2023-03-11","type":"pipeline","source":"BioPharma APAC","summary":"Allorion Therapeutics Raises $50M in Series B Financing for Precision Medicine in Oncology and Autoimmune Diseases - BioPharma APAC","headline":"Allorion Therapeutics Raises $50M in Series B Financing for Precision Medicine in Oncology and Autoimmune Diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOeDVnLUdPRW9rUWVQcGxyYXV5YUNDeVFuSFRUSVRwbVdtUVFyd21ydWc3WjFoV0JhMlRVQ3RMT3gyVGM1c0NUdVgtSG9hSXRCZG4tc0tiUUY3NFFHR3NHOUhDZTU1UVJLb2tCaFQ5VF9ERy1SNXUyOWcyMEJtVmVXOWh0d2VNSHJFNmtjcUxkeUxzUQ?oc=5","date":"2023-03-10","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—Biogen names Stelios Papadopoulos' successor - Fierce Biotech","headline":"Chutes & Ladders—Biogen names Stelios Papadopoulos' successor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQS0EyTE84ZDBya0RhUFRLcTNKNUdudGg1aDJNRTM4Z2RjTENhZlJiRGNXQktyOXFCMDc4YVRhSjgxVWNmNTBjdTNKMm8tUVUyMk5JVUUzRTlCRmRxNVF3M19KU0FaUjZYcmdXV0FydXd1T2ZRYi1qM3g1Ulk1UXpSSEN6YmRYY1ZJZ2ZpdWRn?oc=5","date":"2022-08-02","type":"pipeline","source":"启明创投","summary":"Qiming Monthly Newsletter (November 2021 - January 2022) - 启明创投","headline":"Qiming Monthly Newsletter (November 2021 - January 2022) - 启明创投","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}